Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Q3 2025 value amounting to $729000.0.

  • Insight Molecular Diagnostics' Short-term Investments changed N/A to $729000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $729000.0, marking a year-over-year change of. This contributed to the annual value of $433000.0 for FY2022, which is 5210.18% down from last year.
  • Insight Molecular Diagnostics' Short-term Investments amounted to $729000.0 in Q3 2025.
  • Insight Molecular Diagnostics' 5-year Short-term Investments high stood at $1.1 million for Q2 2021, and its period low was $419000.0 during Q3 2022.
  • In the last 4 years, Insight Molecular Diagnostics' Short-term Investments had a median value of $664500.0 in 2022 and averaged $696600.0.
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 22258.06% in 2021, then plummeted by 5460.46% in 2022.
  • Insight Molecular Diagnostics' Short-term Investments (Quarter) stood at $904000.0 in 2021, then plummeted by 52.1% to $433000.0 in 2022, then rose by 1.85% to $441000.0 in 2023, then skyrocketed by 65.31% to $729000.0 in 2025.
  • Its Short-term Investments stands at $729000.0 for Q3 2025, versus $441000.0 for Q3 2023 and $530000.0 for Q2 2023.